Australia is the first country in the world to legalise the medical use of psychedelics. But without a public subsidy, few Australians will be able to afford them.
The government has missed a chance to better target cost cuts to certain patient groups, for certain medical conditions, and for generic drugs.
Anthony Albanese on Sunday formally launched Labor’s campaign, with promises for low paid women, and aspiring home buyers.
Changes in the latest federal budget will mostly affect people who need multiple medicines throughout the year, perhaps for chronic disease. But there are other ways to reduce drug costs.
The language used to describe medications is confusing, with multiple names for the same drug. A change to prescribing rules from today should go a long way to addressing this issue.
The Pharmacy Guild of Australia was founded in 1928 as an employers’ organisation for the owners of community pharmacies.
The Pharmacy Guild represents the owners of community pharmacies around the country. Their reach into every community and large political donations make them more powerful than other lobby groups.
The Coalition’s record on health is patchy, at best. Meanwhile, Labor is already campaigning hard on Medicare.
Here’s how the Turnbull/Morrison government performed on hospitals, primary care, pharmaceuticals and private health insurance.
New Zealand shows up Australia as badly in the field of pharmaceuticals as it does on the rugby field.
Drug prices in Australia are three times higher than in New Zealand. A key reason is the lack of transparency about taxpayer subsidies for Big Pharma and the companies’ own finances.
People with cystic fibrosis, Australia’s most common inherited condition, have thick mucus, including on the lungs.
Wider availability of the cystic fibrosis drug Kalydeco since May 1, 2017 means younger patients can now access it.
The government is paying too much for pharmaceuticals that are no better than their cheaper counterparts. Let’s fix that.
Australia is spending more than A$500 million a year too much for pharmaceuticals because of a little known loophole that allows drug companies to overcharge the government.
Rare cancers are those where the incidence is less than six cases per 100,000 people.
Should new understandings of how cancers develop and could be targeted mean we should change the way the scheme registers cancer drugs?
Representatives of the 12 Trans-Pacific Partnership (TPP) member countries at a press conference in Atlanta, after a deal was reached.
EPA/Erik S. Lesser
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
As the Australian government tightens its belt, consumers end up spending more of their own money on health.
Nikki Short/AAP Image/AAP
Australians are picking up some of the slack of government belt-tightening by paying more for health, with experts concerned this could reduce the equity in Australia’s health system.
Off-label use is when an approved medicine is prescribed for a different reason, at a different dose, or in different patient groups than originally intended.
The off-label use of medicines is not illegal and it doesn’t mean regulators have specifically “disapproved” its use. But there are a number of issues to consider before using a medicine off-label.
Trade minister Andrew Robb attends negotiations for the Trans Pacific Partnership in Sydney last year.
Dan Himbrechts/AAP Image
Over the next few weeks, the trade minister will be under intense pressure to renege on the government’s commitment to reject anything in the Trans Pacific Partnership that could undermine the PBS.
The leaked measures would have benefited consumers and taxpayers, with small imposition on the lucrative bottom lines of pharmacists and the pharmaceutical industry.
Despite numerous leaks about impending changes to medicines policy, the budget showed savings of just $252.2 million over five years from adjusting the price of a small number of PBS-listed drugs.
The government is playing “hardball” in the talks over the new Community Pharmacy Agreement, according to sources.
medicine picture from www.shutterstock.com
The government is locked in a major battle with pharmacists as it looks for $3 billion in budget savings from the pharmaceutical supply chain.
Despite assurances from Minister for Trade and Investment Andrew Robb, the TPP could negatively affect Australian health policy.
The latest part of the TPP to be leaked is its investment chapter. And like almost everything we know about the secretive negotiations for the agreement, it provides plenty of cause for concern.
Patients pay a contribution towards the cost of their medication to the pharmacist who then claims the difference between what they paid and the patient contribution from the government.
Australians make an average of 14 visits to the pharmacy for medicines and advice every year but most don’t know about the agreement that governs how we buy government-subsidised medicines from them.
A rise in the co-payment for medicines may lead to an increase in the rates of discontinuation for some drugs.
Apart from proposing a co-payment for visiting doctors, the last federal budget also contained a proposal to increase the level of co-payments for medications. The government seems to have given little…